CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2026)

CG Oncology (CGON) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 74.42% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$186.5 million (down 76.66% YoY), and the FY2025 full-year result was -$161.0 million, down 82.87% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$60.1 million, down from -$41.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$12.4 million in Q1 2023 and bottomed at -$60.1 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$22.5 million (2023), against an average of -$29.0 million.
• The widest annual swing landed in 2024, when Net Income towards Common Stockholders fell 16.51%; it then slumped 119.14% in 2025.
• A 4-year view of Net Income towards Common Stockholders shows it stood at -$22.5 million in 2023, then tumbled by 41.39% to -$31.8 million in 2024, then slipped by 29.74% to -$41.3 million in 2025, then sank by 45.68% to -$60.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$60.1 million (Q1 2026), -$41.3 million (Q4 2025), and -$43.7 million (Q3 2025), per Business Quant data.

Peer Comparison